Ticker

Initial XcellaraHeart™ orders ship next week, marking the commercial launch of the Xcellara™ cellular wellness platform; Company prepares XcellaraResilience™ for October launch and highlights the retirement of major convertible debt and 43.25M insider shares. LAS VEGAS, NV / ACCESS Newswire / September 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of science-driven human renewal formulations, today…

Former UFC middleweight champion and current broadcaster will help promote MyndSystem™ as part of a disciplined day-and-night performance routine LAS VEGAS, NV / ACCESS Newswire / August 31, 2026 / BioAdaptives®, Inc. (OTCID:BDPT) announced today that UFC Hall of Famer and former UFC middleweight champion Michael Bisping has joined MyndSystem™ as a paid brand ambassador. The partnership will focus on promoting…

Company outlines adjustments to public float, lender lock-up and leak-out agreements, and growth-funding structure. LAS VEGAS, NV / ACCESS Newswire / August 13, 2026 / BioAdaptives, Inc. (OTCID:BDPT) announced a shareholder update on its current capital restructuring, adjustments in executive equity, and long-term operational strategies.

The flagship product of the new Xcellara™ cellular wellness platform is backed by a randomized, double-blind, placebo-controlled human clinical trial that showed an average increase of 268.8% in circulating stem cells after 4 weeks. LAS VEGAS, NV / ACCESS Newswire / August 12, 2026 / BioAdaptives, Inc. (OTCID:BDPT) announced the official commercial launch and pre-order availability of XcellaraHeart™, a breakthrough,…

Retirement of Largest Outstanding Convertible Debt Clears Runway for High-Growth E-Commerce Rollout of a Targeted Stem Cell Platform LAS VEGAS, NV / ACCESS Newswire / August 3, 2026 / BioAdaptives, Inc. (OTCID:BDPT), a developer of natural, science-backed wellness solutions, today announced that the official opening of its commercial order window for XcellaraHeart™, the flagship product in the company's new…